Non-Aspirin NSAIDs Use is Associated with Lowering of Liver Fibrosis Scores in Patients with Fatty Liver Disease
Fatty liver disease, NSAIDs, Aspirin, Ibuprofen, liver fibrosis, Advance liver disease, Cirrhosis, liver fibrosis indices, NAFLD score, Fibrosis-4 score
Digestive System Diseases | Internal Medicine
Only a few studies are available with appropriate data on the effects of non-aspirin, non-steroidal anti-inflammatory drugs (NSAIDs) use in patients with fatty liver disease. We performed a retrospective study of 1347 patients with imaging studies that showed fatty liver disease from 2016 through 2019. We then determined the change in validated indices using Fibrosis-4 (FIB4) and NAFLD fibrosis score (NFS). Patient clinical information, including NSAIDs use, was collected at baseline and then yearly. Using generalized linear models, we estimated the association between nonaspirin NSAIDs use and change in baseline indices. Non-aspirin NSAIDs use was found to be associated with significant lowering of FIB-4 score (0.596 units lower, p-value <0.0001) and NFS (0.431 units lower, p-value 0.0027) every year.
In this retrospective study of patients with fatty liver disease found on imaging, non-aspirin NSAID use was associated with lowering of fibrosis scores, suggesting that NSAID use might be associated with a lower risk for advanced fibrosis in fatty liver disease.
Publisher or Conference
World Journal of Advanced Research and Reviews
Ogbu IR, Akhondi asl H, Ayutyanont N, Manov A, Manne V. Non-aspirin NSAIDs use is associated with lowering of liver fibrosis scores in patients with fatty liver disease. World Journal of Advanced Research and Reviews. 2021;10(1):230-236. https://doi.org/10.30574/wjarr.2021.10.1.0165